Anzeige
Mehr »
Login
Samstag, 29.03.2025 Börsentäglich über 12.000 News von 695 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P85Z | ISIN: US67080M1036 | Ticker-Symbol:
NASDAQ
28.03.25
20:44 Uhr
12,130 US-Dollar
-0,420
-3,35 %
1-Jahres-Chart
NURIX THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
NURIX THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur NURIX THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiNurix Therapeutics, Inc.: Nurix Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) 2025 Annual Meeting2
21.03.Nurix Therapeutics (NASDAQ:NRIX) Trading Up 4.4% - What's Next?2
17.03.Beyond The Numbers: 8 Analysts Discuss Nurix Therapeutics Stock2
17.03.FDA gewährt Orphan-Drug-Status für Nurix' WM-Behandlung Bexobrutideg2
14.03.Nurix Therapeutics, Inc.: Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)143SAN FRANCISCO, March 14, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
► Artikel lesen
NURIX THERAPEUTICS Aktie jetzt für 0€ handeln
13.03.Nurix Therapeutics, Inc.: Nurix Therapeutics Appoints Drug Development Expert Roy D. Baynes, MB.Bch., M.Med., Ph.D., to Its Board of Directors147SAN FRANCISCO, March 13, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
► Artikel lesen
03.03.Nurix Therapeutics CFO Hans van Houte verkauft Aktien im Wert von 84.387 US-Dollar2
14.02.Nurix Therapeutics, Inc.: Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)103SAN FRANCISCO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
► Artikel lesen
29.01.8 Analysts Have This To Say About Nurix Therapeutics2
28.01.Nurix plans to advance BTK degrader asset for chronic lymphocytic leukemia2
28.01.Nurix Therapeutics GAAP EPS of -$0.75, revenue of $13.28M1
28.01.Nurix Therapeutics, Inc.: Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update176Reported a robust objective response rate of 75.5% from the Phase 1 study of NX-5948 in patients with relapsed/refractory CLL/SLL at the 66th American Society of Hematology Annual Meeting Received...
► Artikel lesen
28.01.Nurix Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans-
28.01.Nurix Therapeutics, Inc. - 10-K, Annual Report-
28.01.Nurix Therapeutics, Inc. - 8-K, Current Report-
22.01.Nurix Therapeutics ernennt neuen Chief Commercial Officer2
22.01.Nurix Therapeutics appoints new chief commercial officer3
22.01.Nurix Therapeutics, Inc.: Nurix Therapeutics Announces Appointment of John Northcott as Chief Commercial Officer219SAN FRANCISCO, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...
► Artikel lesen
13.01.Nurix Therapeutics, Inc. - 8-K, Current Report1
02.01.Chefjuristin von Nurix Therapeutics verkauft Aktien im Wert von 112.000 US-Dollar2
Seite:  Weiter >>
67 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1